GlassScriptPhysician profile
Douglas Lawrence Odea
NPI 1316974132
$6,851.74
in general payments reported to CMS, 2019-2025
42 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $1,387 · 2021: $1,439 · 2022: $751 · 2023: $747 · 2024: $762 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $865.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $829.17 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $797.58 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $744.59 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $620.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.44 | 2019-2025 | Jardiance |
| Pfizer INC. | $351.48 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.22 | 2019-2024 | Trintellix |
| Allergan, INC. | $227.41 | 2019-2020 | |
| Abbott Laboratories | $173.03 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $114.63 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $108.15 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $107.83 | 2020-2023 | Eliquis |
| Amgen INC. | $100.98 | 2020-2024 | Repatha, Otezla |
| Biotronik INC. | $100.52 | 2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Odea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.